Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 182.2 Million EUR | 601.32% |
| 2022 | 22.8 Million EUR | 210.14% |
| 2021 | -18.3 Million EUR | -226.22% |
| 2020 | 13.9 Million EUR | -34.92% |
| 2019 | 25.2 Million EUR | -5.26% |
| 2018 | 29.6 Million EUR | 241.49% |
| 2017 | 5.2 Million EUR | -120.77% |
| 2016 | 56.6 Million EUR | 214.24% |
| 2015 | 65.4 Million EUR | -68.11% |
| 2014 | 82.8 Million EUR | 10.12% |
| 2013 | 82.1 Million EUR | 4.66% |
| 2012 | 78.34 Million EUR | -16.63% |
| 2011 | 75.28 Million EUR | 14.89% |
| 2010 | 81.79 Million EUR | -13.55% |
| 2009 | 88.53 Million EUR | 10.27% |
| 2008 | 89 Million EUR | -69.0% |
| 2007 | 55.87 Million EUR | 13.04% |
| 2006 | 244.86 Million EUR | 15.41% |
| 2005 | 212.16 Million EUR | 573.67% |
| 2004 | 31.49 Million EUR | 68.71% |
| 2003 | 18.66 Million EUR | -29.17% |
| 2002 | 26.35 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 27.3 Million EUR | -42.3% |
| 2024 Q1 | 54.6 Million EUR | 5133.33% |
| 2023 Q3 | 134.8 Million EUR | 317.34% |
| 2023 Q4 | 12.4 Million EUR | -90.8% |
| 2023 Q2 | 32.3 Million EUR | 687.27% |
| 2023 Q1 | -5.5 Million EUR | -10.0% |
| 2023 FY | - EUR | 601.32% |
| 2022 Q3 | -4.4 Million EUR | -266.67% |
| 2022 Q4 | -5 Million EUR | -13.64% |
| 2022 FY | - EUR | 210.14% |
| 2022 Q1 | -600 Thousand EUR | 98.61% |
| 2022 Q2 | -1.2 Million EUR | -100.0% |
| 2021 Q4 | -43.1 Million EUR | -2168.42% |
| 2021 Q1 | -7.3 Million EUR | 31.13% |
| 2021 Q2 | 3 Million EUR | 141.1% |
| 2021 Q3 | -1.9 Million EUR | -163.33% |
| 2021 FY | - EUR | -226.22% |
| 2020 FY | - EUR | -34.92% |
| 2020 Q1 | 2.8 Million EUR | 149.12% |
| 2020 Q2 | -300 Thousand EUR | -110.71% |
| 2020 Q3 | -5.1 Million EUR | -1600.0% |
| 2020 Q4 | -10.6 Million EUR | -107.84% |
| 2019 FY | - EUR | -5.26% |
| 2019 Q4 | -5.7 Million EUR | -418.18% |
| 2019 Q3 | -1.1 Million EUR | -114.47% |
| 2019 Q2 | 7.6 Million EUR | 204.11% |
| 2019 Q1 | -7.3 Million EUR | -10.61% |
| 2018 FY | - EUR | 241.49% |
| 2018 Q4 | -6.6 Million EUR | -240.43% |
| 2018 Q3 | 4.7 Million EUR | -44.71% |
| 2018 Q2 | 8.5 Million EUR | 277.08% |
| 2018 Q1 | -4.8 Million EUR | -242.86% |
| 2017 FY | - EUR | -120.77% |
| 2017 Q4 | -1.4 Million EUR | -131.11% |
| 2017 Q3 | 4.5 Million EUR | -4.26% |
| 2017 Q2 | 4.7 Million EUR | 118.88% |
| 2017 Q1 | -24.9 Million EUR | -163.2% |
| 2016 Q2 | 9.6 Million EUR | 11.63% |
| 2016 Q4 | 39.4 Million EUR | 398.73% |
| 2016 Q3 | 7.9 Million EUR | -17.71% |
| 2016 FY | - EUR | 214.24% |
| 2016 Q1 | 8.6 Million EUR | -47.24% |
| 2015 Q3 | -84.3 Million EUR | -3931.82% |
| 2015 Q2 | 2.2 Million EUR | 2100.0% |
| 2015 Q1 | 100 Thousand EUR | -99.56% |
| 2015 FY | - EUR | -68.11% |
| 2015 Q4 | 16.3 Million EUR | 119.34% |
| 2014 FY | - EUR | 10.12% |
| 2014 Q3 | 8.8 Million EUR | -44.3% |
| 2014 Q4 | 22.8 Million EUR | 159.09% |
| 2014 Q2 | 15.8 Million EUR | 47.66% |
| 2014 Q1 | 10.7 Million EUR | -22.46% |
| 2013 Q4 | 13.8 Million EUR | -1.43% |
| 2013 FY | - EUR | 4.66% |
| 2013 Q2 | 14.1 Million EUR | 19.49% |
| 2013 Q1 | 11.8 Million EUR | 22.78% |
| 2013 Q3 | 14 Million EUR | -0.71% |
| 2012 FY | - EUR | -16.63% |
| 2012 Q2 | 12.5 Million EUR | 20.19% |
| 2012 Q3 | 9.9 Million EUR | -20.8% |
| 2012 Q4 | 9.61 Million EUR | -2.92% |
| 2012 Q1 | 10.4 Million EUR | -68.53% |
| 2011 Q2 | 10.9 Million EUR | 19.78% |
| 2011 Q4 | 33.05 Million EUR | 227.24% |
| 2011 Q3 | 10.1 Million EUR | -7.34% |
| 2011 FY | - EUR | 14.89% |
| 2011 Q1 | 9.1 Million EUR | -53.79% |
| 2010 Q1 | 12.3 Million EUR | -42.44% |
| 2010 Q4 | 19.69 Million EUR | 71.23% |
| 2010 Q2 | 11.4 Million EUR | -7.32% |
| 2010 FY | - EUR | -13.55% |
| 2010 Q3 | 11.5 Million EUR | 0.88% |
| 2009 FY | - EUR | 10.27% |
| 2009 Q4 | 21.37 Million EUR | 32.73% |
| 2009 Q3 | 16.1 Million EUR | -0.62% |
| 2009 Q2 | 16.2 Million EUR | 8.0% |
| 2009 Q1 | 15 Million EUR | 0.0% |
| 2008 FY | - EUR | -69.0% |
| 2007 FY | - EUR | 13.04% |
| 2006 FY | - EUR | 15.41% |
| 2005 FY | - EUR | 573.67% |
| 2004 FY | - EUR | 68.71% |
| 2003 FY | - EUR | -29.17% |
| 2002 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 4869.45% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 356.49% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 76286.494% |
| SQZ Biotechnologies Company | -64.14 Million USD | 384.062% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 6989.907% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 1148.935% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -93.751% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 11961.601% |
| Marizyme, Inc. | -34.28 Million USD | 631.482% |
| Genus plc | 73.7 Million USD | -147.218% |
| Pharming Group N.V. | 9.87 Million USD | -1744.69% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 12349.464% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 5236.738% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 2177.063% |
| ContraFect Corporation | -64.99 Million USD | 380.312% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 13097.5% |
| IMV Inc. | -35.52 Million USD | 612.901% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 7940.538% |
| ONE Bio Corp. | 13.61 Million USD | -1238.422% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 477.797% |
| Mesoblast Limited | -62.38 Million USD | 392.035% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 35270.622% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -5000.784% |
| Genscript Biotech Corporation | -248.71 Million USD | 173.255% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 28910.606% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 8075.525% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 3173.078% |
| Biomind Labs Inc. | -1.03 Million USD | 17711.539% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 6399.428% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 2644.24% |
| Skye Bioscience, Inc. | -13.54 Million USD | 1444.893% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -2709596.609% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 2855.797% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 728900.0% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 4125.456% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 4790.654% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 1248.097% |
| Accustem Sciences Inc. | -3.74 Million USD | 4963.311% |
| EV Biologics, Inc. | -1.26 Million USD | 14478.928% |
| Q BioMed Inc. | -617.62 Thousand USD | 29599.958% |
| GB Sciences, Inc. | -1.41 Million USD | 12932.025% |
| Alpha Cognition Inc. | -9.7 Million USD | 1977.267% |
| CSL Limited | 4.78 Billion USD | 96.195% |
| Agentix Corp. | -1.37 Million USD | 13382.246% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 559.673% |
| Enzolytics Inc. | -2.12 Million USD | 8686.122% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | -11.74 Million USD | 1651.695% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 6048.386% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 7382.285% |
| argenx SE | -216.02 Million USD | 184.343% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 429.243% |
| HST Global, Inc. | -5303.00 USD | 3435891.062% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -14871.241% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 8957.56% |
| Halberd Corporation | -74.27 Thousand USD | 245391.401% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -1957.873% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -47993.674% |
| Zenith Capital Corp. | -8.6 Million USD | 2217.128% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 12255.532% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 7547.493% |
| AVAX Technologies, Inc. | -6.11 Million USD | 3080.707% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 103608.401% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 9585.083% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 1045964.187% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | -1.03 Million USD | 17707.318% |
| Helix BioMedix, Inc. | -1.04 Million USD | 17513.544% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 10511.435% |
| Kadimastem Ltd | -2.62 Million USD | 7042.59% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -7.55 Million USD | 2512.081% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 100714.066% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 412.28 Thousand USD | -44092.945% |
| Cell Source, Inc. | -4.27 Million USD | 4364.456% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 49715.899% |
| Regen BioPharma, Inc. | 1.46 Million USD | -12328.75% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 19546.096% |
| Affymax, Inc. | -14.29 Million USD | 1374.572% |
| Mobile Lads Corp. | -2.24 Million USD | 8229.722% |
| Itoco Inc. | -1.86 Million USD | 9848.555% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 48095.364% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 16426.165% |
| International Stem Cell Corporation | 202 Thousand USD | -90098.02% |
| CytoDyn Inc. | -18.02 Million USD | 1110.594% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 230648.28% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 1490001.055% |
| Qrons Inc. | -40.08 Thousand USD | 454679.477% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 37614.567% |
| SYBLEU INC | -141.57 Thousand USD | 128798.674% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -34444.672% |
| Rebus Holdings, Inc. | -951 Thousand USD | 19258.78% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 17256.147% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 346224.62% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 7500.692% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 607.96% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 404988.889% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 6754.492% |
| Neutra Corp. | -181.24 Thousand USD | 100625.802% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1003.815% |
| PureTech Health plc | -11.62 Million USD | 1667.042% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 1003.877% |
| IXICO plc | -707 Thousand USD | 25870.863% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 2470.852% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 476.867% |
| CSL Limited | 4.73 Billion USD | 96.15% |
| Cellectis S.A. | -92.63 Million USD | 296.684% |